Tag: CBT > DEA Scheduling: Page 3

Cannabis Industry Research

Medical Marijuana Act Signed by Biden Would Hinder Research Under Rescheduling

The Medical Marijuana and Cannabidiol Research Expansion Act’s requirements would remain under Schedule III, a congressional researcher says.

September 20, 2024

Cannabis Advertising

The Complex Impact of Rescheduling Cannabis on Advertising

The penalties for advertising Schedule I drugs don’t apply to Schedule III drugs, but cannabis businesses could be left in a precarious position.

September 17, 2024

Industry Headlines

MMJ BioPharma Suing DEA Over Cannabis Reform, Medical Research

The biopharmaceutical company filed a lawsuit, citing ‘unjustified’ delays in processing an application for medical research.

September 11, 2024

Banking Bill Cannabis Industry

Trump Signals Support for Federal Cannabis Rescheduling, Banking Reform

The GOP presidential candidate said he will focus on unlocking the ‘medical uses of marijuana to a Schedule 3 drug’ if elected in November.

September 9, 2024

2018 Farm Bill Status

4th Circuit Court Rules THC-O Meets Legal Definition of Hemp, Deviating From DEA

The federal court’s interpretation of the 2018 Farm Bill contradicts the Drug Enforcement Administration’s position that THC-O is illegal.

September 9, 2024

Pesticides

Ohio Cannabis, Federal Rescheduling, GTI’s Former Partnership With Bobby George Lead CBT’s Top Stories in August

From Ohio’s sales launch to a rescheduling hearing and to a man facing nine felony charges, don’t miss out on the most-read articles this month.

August 29, 2024

Cannabis Rescheduling

Cannabis Rescheduling No Longer on Fast Track; Hearing Scheduled For December

The DEA will not issue a final rule before the November election now that Administrator Anne Milgram granted an administrative law judge hearing.

August 27, 2024

Interviews & Opinion

Rescheduling Update: How Long Is the Wait? What’s Next?

Government affairs and policy expert David Mangone tells us what we can expect from the DEA as weeks pass following the public comment period, including insights on the DEA’s final review and if a hearing is likely to be granted.

August 8, 2024

Cannabis Rescheduling

Cannabis Rescheduling Nearly ‘Done Deal,’ Story Cannabis CEO Says

Jason Vedadi, the former executive chairman for Harvest Health before its acquisition by Trulieve, talks exclusively with CBT on what he expects from federal rescheduling as the industry awaits the DEA’s final determination.

July 29, 2024

Pesticides

Ohio’s Adult-Use Licensing Process Leads CBT’s Top Stories in July

California’s deadly pesticide contamination, federal cannabis rescheduling and CRISPR gene editing were also among the most-read articles this month.

July 25, 2024

Cannabis Rescheduling

43,000 Comments Filed on Cannabis Rescheduling Proposal as Public Period Closes

The Drug Enforcement Administration will now weigh these comments and potentially hold administrative law hearings before issuing a final rule.

July 23, 2024

Cannabis Rescheduling

9 US Senators Urge VA to Expand Access to Medical Cannabis for America’s Veterans

Sen. Jeff Merkley led the group in a letter to U.S. Secretary of Veterans Affairs Denis McDonough following the DEA’s rescheduling recommendation.

July 19, 2024